GlaxoSmithKline Given “Neutral” Rating at JPMorgan Chase & Co. (GSK)
GlaxoSmithKline (LON:GSK)‘s stock had its “neutral” rating reiterated by stock analysts at JPMorgan Chase & Co. in a report issued on Tuesday, StockRatingsNetwork reports. They currently have a GBX 1,900 ($30.48) price target on the stock. JPMorgan Chase & Co.’s price objective points to a potential upside of 22.58% from the company’s current price.
Shares of GlaxoSmithKline (LON:GSK) traded up 0.03% on Tuesday, hitting GBX 1550.00. The stock had a trading volume of 6,219,456 shares. GlaxoSmithKline has a 1-year low of GBX 1314.00 and a 1-year high of GBX 1816.00. The stock’s 50-day moving average is GBX 1652. and its 200-day moving average is GBX 1640.. The company’s market cap is £75.098 billion.
A number of other firms have also recently commented on GSK. Analysts at Panmure Gordon reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Friday, October 4th. They now have a GBX 1,850 ($29.68) price target on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Wednesday, October 2nd. They now have a GBX 1,850 ($29.68) price target on the stock. Finally, analysts at Societe Generale reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday, October 1st. They now have a GBX 2,000 ($32.09) price target on the stock. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of GBX 1,657.22 ($26.59).
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.